The FDA approved Miplyffa for the treatment of Niemann-Pick disease.
2 reports, 1 independent
Updated Fri 00:00
Still developing
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA approved Miplyffa for the treatment of Niemann-Pick disease.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.The approved therapy is now driving revenue growth for Zevra Therapeutics.1 source
- FDA grants approval for Miplyffa, a drug developed by Zevra Therapeutics, for Niemann-Pick disease.
Keep exploring
The entities involved
Related events
- FDA granted approvals for RASONQUE and WELTRUZA on November 4, 2026.
- An integrated GLP-1 program is utilizing medications that have received approval from the FDA.
- Ohio covers FDA-approved uses of drugs, supported by scientific basis from the National Institutes of Health.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Coverage
Newest first; wire copies grouped- themarketsdaily.com
- Unknown outlet